SCHEMBL2963487

SCHEMBL2963487

CC1=CCc2cc(Br)ccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 2/20 0.39
PGR P06401 2/20 0.39
TDP2 O95551 1/20 0.38
PARP10 Q53GL7 1/20 0.38
PARP11 Q9NR21 1/20 0.38
SRD5A1 P18405 2/20 0.37
SRD5A2 P31213 1/20 0.37
S100A4 P26447 1/20 0.35
PNMT P11086 4/20 0.35
ADRA2A P08913 3/20 0.35
ADRA2B P18089 3/20 0.35
ADRA2C P18825 3/20 0.35
CYP19A1 P11511 2/20 0.33
CYP11B1 P15538 2/20 0.33
CYP11B2 P19099 2/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
CA6 P23280 1/20 0.33
ASIC3 Q9UHC3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2974512 0.83 TDP1 (0.38) METAP1PGRTDP2PARP10S100A4
SCHEMBL17028711 0.80 PARP10 (0.43) METAP1PGRTDP2PARP10PARP11
SCHEMBL21694411 0.78 METAP1 (0.41) METAP1PARP10PARP11SRD5A1CA1
SCHEMBL29427206 0.78 METAP1 (0.41) METAP1PARP10PARP11SRD5A1CA1
SCHEMBL18769959 0.75 METAP1 (0.39) METAP1TDP2PARP10PARP11SRD5A1
SCHEMBL2968043 0.75 METAP1 (0.39) METAP1TDP2PARP10PARP11SRD5A1
SCHEMBL29544 0.75 METAP1 (0.39) METAP1PGRSRD5A1SRD5A2S100A4
SCHEMBL2975322 0.75 METAP1 (0.36) METAP1PGRTDP2PARP10PARP11
SCHEMBL2963071 0.75 SRD5A1 (0.38) METAP1TDP2PARP10PARP11SRD5A1
SCHEMBL2959482 0.75 MPO (0.42) METAP1PGRTDP2PARP10PARP11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250032476-A1 ALPHA-2A ADRENERGIC RECEPTOR MODULATORS AND USES THEREOF UNIV CALIFORNIA (US) 2025-01-30 US disclosed
EP-4426287-A1 ALPHA-2A ADRENERGIC RECEPTOR MODULATORS AND USES THEREOF The Regents of the University of California (US) 2024-09-11 EP disclosed
WO-2023081800-A1 ALPHA-2A ADRENERGIC RECEPTOR MODULATORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-05-11 WO disclosed
WO-2017183927-A1 NOVEL HETEROCYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER 한국화학연구원 2017-10-26 WO disclosed
US-9777008-B2 PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2017-10-03 US disclosed
US-20170114061-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-04-27 US disclosed
US-20160214985-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-07-28 US disclosed
US-9388173-B2 PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2016-07-12 US disclosed
US-20150133427-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2015-05-14 US disclosed
US-8906900-B2 PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2014-12-09 US disclosed
US-20140228343-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-08-14 US disclosed
US-7763562-B2 Heteroatom bridged metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2010-07-27 US disclosed
US-20070135597-A1 Heteroatom bridged metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. 2007-06-14 US disclosed
WO-2006065809-A2 HETEROATOM BRIDGED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION EXXONMOBIL CHEMICAL PATENTS INC. (US) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133427-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 METAP1 1562/4885PGR 4369/4885TDP2 964/4885
US-20160214985-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 METAP1 1721/4885PGR 4332/4885TDP2 1015/4885
US-20140228343-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 METAP1 1562/4885PGR 4369/4885TDP2 964/4885
US-20170114061-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 METAP1 1562/4885PGR 4369/4885TDP2 964/4885
US-20070135597-A1 Heteroatom bridged metallocene compounds for olefin polymerization AP2M1, AP1M1, PYM1 METAP1 1352/4885PGR 3088/4885TDP2 4139/4885
US-20250032476-A1 ALPHA-2A ADRENERGIC RECEPTOR MODULATORS AND USES THEREOF ADRA2A, ADRB2, ADRA2C METAP1 1486/4885PGR 2013/4885TDP2 1315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.